About AudentesTherapeutics
AudentesTherapeutics is a company based in San Francisco (United States) founded in 2013 was acquired by Astellas Pharma in December 2019.. AudentesTherapeutics has raised $137.5 million across 3 funding rounds from investors including T. Rowe Price, TD Securities and Astellas Pharma. The company has 404 employees as of December 31, 2021. AudentesTherapeutics has completed 1 acquisition, including Cardiogen Biosciences. AudentesTherapeutics operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Denali Therapeutics, among others.
- Headquarter San Francisco, United States
- Employees 404 as on 31 Dec, 2021
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Audentes Therapeutics, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$137.5 M (USD)
in 3 rounds
-
Latest Funding Round
$65 M (USD), Series C
Oct 19, 2015
-
Investors
T. Rowe Price
& 13 more
-
Employee Count
404
as on Dec 31, 2021
- Investments & Acquisitions
-
Acquired by
Astellas Pharma
(Dec 02, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of AudentesTherapeutics
AudentesTherapeutics is a publicly listed company on the NASDAQ with ticker symbol BOLD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Unlock access to complete
Unlock access to complete
Leadership Team
91 people
Software Development Team
63 people
Sales and Marketing
27 people
Operations Team
25 people
Product Management Team
24 people
Human Resources and Administration
19 people
Head Team
19 people
Senior Team
18 people
Unlock access to complete
Funding Insights of AudentesTherapeutics
AudentesTherapeutics has successfully raised a total of $137.5M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $65 million completed in October 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series C — $65.0M
-
First Round
First Round
(18 Jul 2013)
- Investors Count 13
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2015 | Amount | Series C - AudentesTherapeutics | Valuation | Sofinnova Investments , Redmile Group | |
| Dec, 2014 | Amount | Series B - AudentesTherapeutics | Valuation | Deerfield Triarc Capital | |
| Jul, 2013 | Amount | Series A - AudentesTherapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in AudentesTherapeutics
AudentesTherapeutics has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include T. Rowe Price, TD Securities and Astellas Pharma. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biotech funding, drug development support, and investment in life sciences.
|
Founded Year | Domain | Location | |
|
Early-stage and late-stage biotech and finance companies are funded.
|
Founded Year | Domain | Location | |
|
Multi-stage investment firm invests in healthcare and life sciences companies
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by AudentesTherapeutics
AudentesTherapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Cardiogen Biosciences. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
AAV gene therapies are developed for rare inherited arrhythmogenic diseases.
|
2014 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - AudentesTherapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Audentestherapeutics Comparisons
Competitors of AudentesTherapeutics
AudentesTherapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Denali Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
Developer of drugs for treating rare and autoimmune diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Audentestherapeutics
Frequently Asked Questions about AudentesTherapeutics
When was AudentesTherapeutics founded?
AudentesTherapeutics was founded in 2013.
Where is AudentesTherapeutics located?
AudentesTherapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Is AudentesTherapeutics a funded company?
AudentesTherapeutics is a funded company, having raised a total of $137.5M across 3 funding rounds to date. The company's 1st funding round was a Series A of $30M, raised on Jul 18, 2013.
How many employees does AudentesTherapeutics have?
As of Dec 31, 2021, the latest employee count at AudentesTherapeutics is 404.
What does AudentesTherapeutics do?
Audentes Therapeutics was established in 2013 in San Francisco, United States, within the biotechnology sector. Focus is placed on developing adeno-associated virus-based gene replacement therapies for rare genetic diseases. The lead candidate, AT845, delivers a functional acid alpha-glucosidase gene to muscle cells for adults with late-onset Pompe disease. Pipeline efforts also target X-linked myotubular myopathy, Duchenne muscular dystrophy, and myotonic dystrophy type 1.
Who are the top competitors of AudentesTherapeutics?
AudentesTherapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Is AudentesTherapeutics publicly traded?
Yes, AudentesTherapeutics is publicly traded on NASDAQ under the ticker symbol BOLD.
How many acquisitions has AudentesTherapeutics made?
AudentesTherapeutics has made 1 acquisition, including Cardiogen Biosciences.
Who are AudentesTherapeutics's investors?
AudentesTherapeutics has 14 investors. Key investors include T. Rowe Price, TD Securities, Astellas Pharma, Orbimed, and RA Capital.
What is AudentesTherapeutics's ticker symbol?
The ticker symbol of AudentesTherapeutics is BOLD on NASDAQ.